William Plunkett

31.7k total citations · 5 hit papers
346 papers, 21.9k citations indexed

About

William Plunkett is a scholar working on Molecular Biology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, William Plunkett has authored 346 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Molecular Biology, 138 papers in Genetics and 113 papers in Public Health, Environmental and Occupational Health. Recurrent topics in William Plunkett's work include Chronic Lymphocytic Leukemia Research (135 papers), Acute Lymphoblastic Leukemia research (112 papers) and Biochemical and Molecular Research (86 papers). William Plunkett is often cited by papers focused on Chronic Lymphocytic Leukemia Research (135 papers), Acute Lymphoblastic Leukemia research (112 papers) and Biochemical and Molecular Research (86 papers). William Plunkett collaborates with scholars based in United States, Netherlands and Japan. William Plunkett's co-authors include Peng Huang, Varsha Gandhi, Michael J. Keating, Sherri Chubb, Hagop M. Kantarjian, Larry W. Hertel, Gerald B. Grindey, Volker Heinemann, Deepa Sampath and Elihu H. Estey and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

William Plunkett

343 papers receiving 21.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

1991 754 citations Peng Huang, Sherri Chubb et al. profile →
Superoxide dismutase as a target for the selective killing of cancer cells

2000 722 citations Peng Huang, Michael J. Keating et al. profile →
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

2005 704 citations Michael J. Keating, William Plunkett et al. profile →
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

1995 646 citations William Plunkett, Peng Huang et al. profile →
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

2015 350 citations William G. Wierda, William Plunkett et al. profile →

Peers

Countries citing papers authored by William Plunkett

Since Specialization

Citations

This map shows the geographic impact of William Plunkett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Plunkett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Plunkett more than expected).

Fields of papers citing papers by William Plunkett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Plunkett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Plunkett. The network helps show where William Plunkett may publish in the future.

Co-authorship network of co-authors of William Plunkett

This figure shows the co-authorship network connecting the top 25 collaborators of William Plunkett. A scholar is included among the top collaborators of William Plunkett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Plunkett. William Plunkett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells 2022 ·Leukemia ·Rong Chen, Yuling Chen, Ping Xiong, Daniella Zheleva, David Blake, Michael J. Keating, William G. Wierda, William Plunkett	20
2	CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death 2019 ·Molecular Cancer Therapeutics ·Xiaojun Liu, Yingjun Jiang, Kei‐ichi Takata, Billie Nowak, Chaomei Liu, Richard D. Wood, Walter N. Hittelman, William Plunkett	6
3	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia 2019 ·Cancer Immunology Research ·(unknown), Ronghua Zhang, Cristina Ivan, Giovanni Galletti, Karen Clise-Dwyer, Federica Barbaglio, Lydia Scarfò, Miguel Aracil, Christian Klein, William G. Wierda, William Plunkett, Federico Caligaris‐Cappio, Varsha Gandhi, Michael J. Keating, Maria Teresa Sabrina Bertilaccio	38
4	Phase 1/2 study of DFP‐10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia 2019 ·Cancer ·Hagop M. Kantarjian, Elias Jabbour, Guillermo Garcia‐Manero, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Gautam Borthakur, Nitin Jain, (unknown), Monica Kwari, Farhad Ravandi, Barry Anderson, (unknown), Cheng Jin, Chun Zhang, William Plunkett	4
5	Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia 2019 ·Leukemia ·Rong Chen, Mingzhao Zhu, Rajan Chaudhari, Omar Robles, Yuling Chen, Wesley Skillern, Qun Qin, William G. Wierda, Shuxing Zhang, Kenneth G. Hull, Daniel Romo, William Plunkett	13
6	TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors 2017 ·Molecular Cancer Therapeutics ·Muthana Al Abo, Hiroyuki Sasanuma, Xiaojun Liu, Vinodh N. Rajapakse, (unknown), Evgeny Kiselev, Shunichi Takeda, William Plunkett, Yves Pommier	25
7	Mechanism-Based Drug Combinations with the DNA Strand–Breaking Nucleoside Analog CNDAC 2016 ·Molecular Cancer Therapeutics ·Xiaojun Liu, Yingjun Jiang, Billie Nowak, (unknown), William Plunkett	4
8	HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia 2016 ·Clinical Cancer Research ·(unknown), Brett Ewald, (unknown), Chaomei Liu, Melanie Sulda, Dimitrios Papaioannou, Ramiro Garzon, James S. Blachly, William Plunkett, Deepa Sampath	53
9	Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe 2016 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), (unknown), Rong Chen, Yuling Chen, William Plunkett, Xin Cheng, (unknown), Earl F. Albone, Jun O. Liu, Daniel Romo	23
10	Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease 2011 ·Clinical Cancer Research ·(unknown), Deepa Sampath, Brett Ewald, Rong Chen, William G. Wierda, William Plunkett	7
11	Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line 2010 ·Cancer Research ·Rong Chen, Sherri Chubb, Tiewei Cheng, Rachael E. Hawtin, Varsha Gandhi, William Plunkett	26
12	Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219 2009 ·Clinical Cancer Research ·Cheng‐Yu Tsai, Adrian S. Ray, Daniel B. Tumas, Michael J. Keating, Hans Reiser, William Plunkett	11
13	Repair of 2′- C -Cyano-2′-Deoxy-1-β- d - arabino -Pentofuranosylcytosine–Induced DNA Single-Strand Breaks by Transcription-Coupled Nucleotide Excision Repair 2008 ·Cancer Research ·Yaqing Wang, Xiaojun Liu, Akira Matsuda, William Plunkett	20
14	H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation 2007 ·Molecular Cancer Therapeutics ·Brett Ewald, Deepa Sampath, William Plunkett	167
15	Molecular Basis for G2 Arrest Induced by 2′- C -Cyano-2′-Deoxy-1-β- d - Arabino -Pentofuranosylcytosine and Consequences of Checkpoint Abrogation 2005 ·Cancer Research ·Xiaojun Liu, Ying Guo, Ye‐Xiong Li, Yingjun Jiang, Sherri Chubb, Atsushi Azuma, Peng Huang, Akira Matsuda, Walter N. Hittelman, William Plunkett	40
16	Complete hematologic and cytogenetic response to 2-amino-9-?-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase 1999 ·Cancer ·Álvaro Aguayo, Jörge E. Cortes, Hagop M. Kantarjian, Miloslav Beran, Varsha Gandhi, William Plunkett, Joanne Kurtzberg, Michael J. Keating	14
17	Introduction: Gemcitabine - Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog 1995 ·Seminars in Oncology ·Godefridus J. Peters, William Plunkett	15
18	Apoptosis in chronic lymphocytic leukemia 1994 ·L. E. Robertson, Peng Huang, Michael J. Keating, William Plunkett	4
19	Comparison of the action of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ARA-A) with 9-β-D-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells 9-β-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells 1979 ·Proceedings of the American Association for Cancer Research ·William Plunkett, Sherri Chubb, (unknown)	1
20	Potentiation of analogs of adenosine by an inhibitor of adenosine deaminase 1975 ·Proceedings of the American Association for Cancer Research ·William Plunkett, Shira Cohen	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact